Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DART: Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer
NCT03999710Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2019
- Primary completion
- Oct 2026
- Countries
- 1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Drugs
- durvalumab
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival at 2 years. Started Jul 2019; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Non-Small Cell Lung Cancer
Durvalumab + Thoracic Radiation Therapy
03
Who it enrols
Adults with newly diagnosed or recurrent locally-advanced NSCLC (stage II-III) ineligible for resection and concurrent chemoradiotherapy, with ECOG PS 0-2, adequate organ function, and no actionable EGFR or ALK mutations.
04
Endpoints
Primary
Progression-Free Survival
Beyond the preview
Go deeper on NCT03999710.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03999710.